YER097W Antibody

What is YER097W and in which organism is it found?

YER097W is a protein-coding gene found in Saccharomyces cerevisiae (Baker's yeast), specifically in strain ATCC 204508/S288c. It is referenced in the UniProt database with the accession number P40062 . YER097W has been investigated in various yeast genetic studies, including those examining chromatin immunoprecipitation (ChIP) analysis, where it has been studied alongside genes like GAL1, SWR1, and ribosomal protein genes (RPL13A and RPS16B) .

What types of YER097W antibodies are available for research applications?

The primary commercially available YER097W antibody is a polyclonal antibody raised in rabbits against recombinant Saccharomyces cerevisiae (strain ATCC 204508/S288c) YER097W protein. These antibodies are typically provided in liquid form with specific storage buffers designed to maintain stability and functionality . While monoclonal antibodies might offer greater specificity for particular epitopes, the current literature primarily references polyclonal antibodies for YER097W detection.

What are the recommended storage conditions for YER097W antibodies?

YER097W antibodies should be stored at -20°C or -80°C upon receipt. Repeated freeze-thaw cycles should be avoided to maintain antibody integrity and performance. Most commercial preparations are supplied in a storage buffer containing preservatives (such as 0.03% Proclin 300) and stabilizers (50% Glycerol in 0.01M PBS, pH 7.4) . These components help maintain antibody structure and function during storage.

What validated applications exist for YER097W antibodies?

YER097W antibodies have been validated for several experimental applications, particularly:

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection of YER097W protein

• Western Blot (WB): For identifying YER097W protein in yeast cell lysates

These applications have been specifically tested and validated to ensure proper identification of the target antigen . The antibodies are designed for research use only and not for diagnostic or therapeutic applications.

How can researchers validate YER097W antibodies for specificity?

Rigorous antibody validation should follow a systematic approach similar to the methodology described for other antibodies:

• Generate knockout (KO) cell lines using CRISPR/Cas9 gene editing in yeast

• Compare antibody reactivity between parental and KO lines using immunoblotting

• Verify signal reduction or elimination in the KO line

• Confirm specificity with alternative detection methods

A robust validation would show a strong signal in parental cell lysates that is significantly reduced or absent in KO lysates. This knockout-validation approach has become the gold standard for antibody specificity testing in molecular biology research .

What are the appropriate controls when using YER097W antibodies in Western blotting?

When performing Western blot experiments with YER097W antibodies, researchers should include:

• Positive control: Lysate from wild-type S. cerevisiae strain ATCC 204508/S288c

• Negative control: If available, lysate from YER097W knockout strain

• Loading control: Detection of a constitutively expressed yeast protein (e.g., actin)

• Secondary antibody control: Incubation with secondary antibody alone to detect non-specific binding

• Ponceau S staining: To verify even loading and efficient transfer of proteins

For quantitative Western blots, researchers should consider using fluorescent secondary antibodies with systems like the LI-COR Odyssey Imaging System, which provides more accurate quantification than traditional chemiluminescence methods .

How can immunoprecipitation protocols be optimized for YER097W antibodies?

Optimizing immunoprecipitation (IP) with YER097W antibodies requires systematic protocol refinement:

• Pre-couple antibodies (1-5 μg) to protein A- or protein G-Sepharose beads as appropriate for rabbit IgG

• Prepare yeast lysates in detergent-containing buffer (e.g., 1% Triton X-100) to extract both cytosolic and membrane-associated proteins

• Incubate lysates with antibody-bead conjugates (typically 1 mg of lysate per IP reaction)

• Include controls:

  • Beads alone with lysate (to detect non-specific binding to beads)

  • Antibody-bead conjugates with buffer alone (no lysate)

• After washing, analyze immunoprecipitates by immunoblotting with a second validation antibody if available

• Quantify IP efficiency by analyzing the unbound fraction to determine percentage of target protein captured

Successful IP protocols typically capture 50-70% of the target protein from the lysate, and efficiency can be quantified using fluorescent secondary antibodies and appropriate imaging systems .

What approaches can be used to minimize cross-reactivity when using YER097W antibodies?

Cross-reactivity is a common challenge with antibodies. For YER097W antibodies, researchers should:

• Pre-adsorb antibodies against lysates from YER097W knockout strains if available

• Optimize blocking conditions (try different blocking agents: 5% BSA, 5% non-fat dry milk, commercial blocking buffers)

• Increase wash stringency by adjusting salt concentration or adding mild detergents

• Test for cross-reactivity with related yeast proteins using bioinformatics tools to identify proteins with sequence similarity

• Perform competitive binding assays with purified recombinant YER097W protein

Western blot assays with various yeast strains can help identify potential cross-reactivity. Studies of antibodies against other proteins have shown that even well-characterized antibodies may exhibit cross-reactivity with structurally similar epitopes, as demonstrated in research on bacterial and human proteins .

How can YER097W antibodies be used effectively in chromatin immunoprecipitation (ChIP) experiments?

For effective ChIP experiments with YER097W antibodies:

• Cross-link yeast cells with formaldehyde (typically 1% for 10-15 minutes)

• Lyse cells and shear chromatin to fragments of 200-500 bp using sonication

• Pre-clear chromatin with protein A/G beads before immunoprecipitation

• Use 2-5 μg of YER097W antibody per ChIP reaction

• Include appropriate controls:

  • Input chromatin (pre-immunoprecipitation)

  • Non-specific IgG control

  • Positive control (antibody against a known chromatin-associated protein)

• Analyze enrichment at expected locations (e.g., GAL1, SWR1, RPL13A, or RPS16B promoters) by qPCR

• Compare enrichment to negative genomic regions not expected to bind YER097W

The literature indicates that YER097W association with specific gene promoters can be effectively analyzed using ChIP with appropriate anti-YER097W antibodies .

How can researchers troubleshoot weak or non-specific signals when using YER097W antibodies?

When facing weak or non-specific signals:

• Optimize antibody concentration (try a titration series from 1:100 to 1:5000)

• Adjust incubation conditions (temperature, duration, buffer composition)

• Test different epitope retrieval methods if applicable

• Evaluate different membrane types for Western blotting (PVDF vs. nitrocellulose)

• Increase protein loading (up to 50-100 μg of total protein per lane)

• Try alternative detection systems (chemiluminescence vs. fluorescence)

• Use fresh antibody aliquots to avoid potential degradation from freeze-thaw cycles

• Optimize secondary antibody concentration and incubation conditions

Signal specificity can be confirmed by comparing results with multiple antibodies targeting different epitopes of YER097W when available.

What is the recommended methodology for quantifying YER097W expression using antibody-based approaches?

For precise quantification of YER097W expression:

• Use quantitative Western blotting with fluorescent secondary antibodies

• Include a standard curve with known quantities of purified recombinant YER097W

• Ensure linear dynamic range by testing multiple exposure times or dilutions

• Normalize signal to appropriate housekeeping proteins

• Use software like ImageJ or dedicated platforms like LI-COR Odyssey for densitometric analysis

• Consider complementary approaches such as mass spectrometry for absolute quantification

• Perform biological replicates (minimum n=3) and appropriate statistical analysis

When comparing expression levels across conditions, it's essential to maintain consistent sample preparation, loading, transfer, and detection protocols to ensure comparable results.

How do different YER097W antibody clones compare in sensitivity and specificity?

While the search results don't provide a direct comparison of different YER097W antibody clones, studies of other proteins suggest that antibody performance can vary significantly between clones and manufacturers. When evaluating different antibodies:

• Test multiple antibodies in parallel using identical samples and protocols

• Compare signal-to-noise ratios across different applications

• Evaluate epitope specificity through peptide competition assays

• Assess batch-to-batch consistency with standardized positive controls

• Compare sensitivity by titrating antibody concentrations

• Document and report detailed characterization data to benefit the research community

The systematic evaluation approach described for C9ORF72 antibodies provides an excellent template for comparing YER097W antibody performance, revealing that some antibodies may excel in certain applications (like Western blotting) while performing poorly in others (like immunoprecipitation) .

How does antibody-based detection of YER097W compare with other detection methods?

Antibody-based detection methods should be considered alongside complementary approaches:

This comparative approach allows researchers to verify findings across multiple methodologies, increasing confidence in results and addressing the limitations inherent to any single technique .

What are the current limitations in YER097W antibody research and future directions?

Current limitations in YER097W antibody research include:

• Limited availability of monoclonal antibodies targeting different epitopes

• Incomplete validation across all potential applications

• Lack of systematic cross-reactivity testing against the yeast proteome

• Limited structural information about the antibody-epitope interaction

Future research directions should focus on:

• Development of comprehensive validation standards similar to those established for other antibodies

• Application of CRISPR/Cas9-based validation approaches

• Generation of monoclonal antibodies with defined epitope specificities

• Integration with emerging proteomics technologies for improved quantitation

• Development of application-specific validation criteria